Through PPI network construction, we predicted that the core biological targets of YTG for IPF treatment were STAT3, SRC, MAPK3, MAPK1, RELA, PTPN11, JUN, MAPK14, STAT1, and EGFR. This evidence concerns the gene MAPK14 and idiopathic pulmonary fibrosis.